


Metabolism of porphyrins



D'Eustachio, P., Jassal, B., Sassa, S.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/faq-fair-use/).

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the [Reactome Textbook](https://reactome.org/Textbook/).

21/09/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 89

This document contains 3 pathways ([see Table of Contents](#))

Stable identifier: R-HSA-189445



Porphyrins readily combine with metals by coordinating them in the central cavity. Iron (heme) and magnesium (chlorophyll) are two well known examples although zinc, copper, nickel and cobalt form other known metal-containing porphyrins. A porphyrin which has no metal in the cavity is called a *free base*.

Some iron-containing porphyrins are called hemes (heme-containing proteins or hemoproteins) and these are found extensively in nature i.e. hemoglobin. Hemoglobin is quantitatively the most important hemoprotein. The hemoglobin iron is the transfer site of oxygen and carries it in the blood all round the body for cell respiration. Other examples are cytochromes present in mitochondria and endoplasmic reticulum which takes part in electron transfer events, catalase and peroxidase which protect the body against the oxidant hydrogen peroxide and tryptophan oxygenase which is present in intermediary metabolism. Hemoproteins are synthesized in all mammalian cells and the major sites are erythropoietic tissue and the liver.

The processes by which heme is synthesized, transported, and metabolized are a critical part of human iron metabolism (Severance and Hamze 2009); here the core processes of heme biosynthesis and catabolism have been annotated.


Editions

2007-01-24	Reviewed	Sassa, S.
2009-05-19	Revised	D'Eustachio, P.

Heme biosynthesis ↗

Location: [Metabolism of porphyrins](#)

Stable identifier: R-HSA-189451



Although heme is synthesised in virtually all tissues, the principal sites of synthesis are erythroid cells (~85%) and hepatocytes (most of the remainder). Eight enzymes are involved in heme biosynthesis, four each in the mitochondria and the cytosol (Layer et al. 2010). The process starts in the mitochondria with the condensation of succinyl CoA (from the TCA cycle) and glycine to form 5-aminolevulinate (ALA). The next four steps take place in the cytosol. Two molecules of ALA are condensed to form the monopyrrole porphobilinogen (PBG). The next two steps convert four molecules of PBG into the cyclic tetrapyrrole uroporphyringen III, which is then decarboxylated into coproporphyrinogen III. The last three steps occur in the mitochondria and involve modifications to the tetrapyrrole side chains and finally, insertion of iron. In addition to these synthetic steps, a spontaneous cytosolic reaction allows the formation of uroporphyringen I which is then enzymatically decarboxylated to coproporphyrinogen I, which cannot be metabolized further in humans. Also, lead can inactivate ALAD, the enzyme that catalyzes PBG synthesis, and ferrochelatase, the enzyme that catalyzes heme synthesis (Ponka et al. 1999, Aijoka et al. 2006).

The porphyrias are disorders that arise from defects in the enzymes of heme biosynthesis. Defective pathway enzymes after ALA synthase result in accumulated substrates which can cause either skin problems, neurological complications, or both due to their toxicity in higher concentrations. They are broadly classified as hepatic porphyrias or erythropoietic porphyrias, based on the site of the overproduction of the substrate. Each defect is described together with the reaction it affects (Peoc'h et al. 2016).

Literature references

Heinz, DW., Jahn, D., Layer, G., Reichelt, J. (2010). Structure and function of enzymes in heme biosynthesis. *Protein Sci.*, 19, 1137-61. ↗

Phillips, JD., Ajioka, RS., Kushner, JP. (2006). Biosynthesis of heme in mammals. *Biochim Biophys Acta*, 1763, 723-36. ↗

Deybach, JC., Puy, H., Peoc'h, K., Talbi, N., Gouya, L., Martin-Schmitt, C. (2016). [Porphyrias and haem related disorders]. *Rev Med Interne*, 37, 173-85. ↗

Ponka, P. (1999). Cell biology of heme. *Am J Med Sci*, 318, 241-56. ↗


Editions

2007-01-24	Authored, Edited	Jassal, B., D'Eustachio, P.
2007-01-24	Reviewed	Sassa, S.
2009-05-19	Revised	D'Eustachio, P.
2019-09-18	Revised	Jassal, B.
2023-11-22	Revised	D'Eustachio, P.

Heme degradation ↗

Location: [Metabolism of porphyrins](#)

Stable identifier: R-HSA-189483



Most of the heme degraded in humans comes from hemoglobin. Approximately 6-8 grams of hemoglobin is degraded daily which is equivalent to approximately 300 milligrams of heme per day. Heme is not recycled so it must be degraded and excreted. The iron, however, is conserved. There are two steps to heme degradation;

1. cleavage of the heme ring by a microsomal heme oxygenase producing biliverdin
2. biliverdin is reduced to bilirubin.

Bilirubin can then be conjugated with glucuronic acid and excreted.

Literature references

Soares, MP., Otterbein, LE., Yamashita, K., Bach, FH. (2003). Heme oxygenase-1: unleashing the protective properties of heme. *Trends Immunol*, 24, 449-55. ↗

Editions

2007-01-24	Reviewed	Sassa, S.
2009-05-19	Revised	D'Eustachio, P.
2019-09-18	Revised	Jassal, B.

Table of Contents

Introduction	1
❖ Metabolism of porphyrins	2
❖ Heme biosynthesis	3
❖ Heme degradation	4
Table of Contents	5